Physician profile
Kala Young
NPI 1871044826
$5,189.84
in general payments reported to CMS, 2019-2025
45 companies · $29.13 in 2025
The $29.13 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,568 · 2022: $2,593 · 2025: $29.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $491.65 | 2021-2022 | |
| Abbvie INC. | $484.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $469.23 | 2021-2022 | |
| Ucb, INC. | $405.18 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $228.23 | 2021-2025 | |
| Biogen, INC. | $216.64 | 2021-2022 | |
| Eisai INC. | $211.34 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $190.40 | 2021 | |
| Celgene Corporation | $174.87 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $151.53 | 2022 | |
| Currax Pharmaceuticals LLC | $151.39 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $141.03 | 2021-2022 | |
| Sk Life Science, INC. | $140.44 | 2021-2022 | |
| Genzyme Corporation | $137.92 | 2021-2022 | |
| Allergan, INC. | $129.53 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.